Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab with Adakitug or Cabiralizumab in Advanced HCC
NCT04050462Phase 2Terminated
- Sponsor
- NYU Langone Health
- Start
- Sep 2019
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of adakitug, cabiralizumab in hepatocellular carcinoma (HCC), sponsored by NYU Langone Health. Started Sep 2019; status: terminated.
02
Drugs
adakitugcabiralizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04050462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04050462.